PARK7 and non-small cell lung carcinoma: Furthermore, our in vitro demonstrated that inhibition of DJ-1 may overcome cisplatin resistance, which suggesting DJ-1 might serve as a potential target for the reversal of drug resistance in NSCLC patients, and ultimately lead to improved clinical outcomes.